Publications

Title Credits Expiration Date
Oncology Briefings Vol. 6, No. 11 Inhibitors of the mTOR and VEGF Pathways in RCC 0.5 Dec 31, 2009
Monographs in Renal Cell Carcinoma Vol. 3, No. 1 Antiangiogenic Therapy in RCC

mTOR Inhibitors in Metastatic RCC 		1 Dec 30, 2009
OncoLogue™: Improving Outcomes in Locally Advanced Squamous Cell Carcinoma of the Head and Neck With Targeted Therapy and Contemporary Induction Regimens Improving Outcomes in Locally Advanced SCCHN 0.5 Dec 24, 2009
Oncology Briefings Vol. 6, No. 9 Targeted Agents in Advanced Thyroid Cancer 0.5 Dec 18, 2009
Cancer Summaries & Commentaries Vol. 1, No. 5 Docetaxel Plus Placebo or Bevacizumab in Locally Recurrent/Metastatic Breast Cancer

Docetaxel/Epirubicin vs. Docetaxel/Capecitabine in LABC/MBC

Trastuzumab/Pertuzumab in Patients With HER2-Positive MBC

First-line Lapatinib/Pazopanib in HER2-Positive LABC/MBC

Lapatinib/Bevacizumab in HER2-Positive MBC

Nomogram to Predict Brain Metastasis in MBC 		1 Dec 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 9 Adjuvant AI Therapy in Hormone Receptor–Positive Breast Cancer 1 Dec 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 8 Bone Health in a Postmenopausal Patient With HR+ Early-Stage Breast Cancer 1 Dec 11, 2009
OncoLogue™: Advances in Epidermal Growth Factor Receptor–Targeted Therapy for Non–Small-Cell Lung Cancer Advances in EGFR-Targeted Therapy for NSCLC 0.5 Nov 26, 2009
Biological Therapy of Breast Cancer Vol. 9, No. 2 Next Generation of Targeted Therapies in Breast Cancer

Are Anthracyclines Still Needed? 		1 Nov 25, 2009
Oncology Briefings VEGF/VEGFR Agents in Advanced/Persistent Ovarian Cancer 0.5 Nov 25, 2009
Oncology Briefings Vol. 6, No. 8 EndothelinA Receptor Antagonists in Prostate Cancer 0.5 Nov 25, 2009
Oncology Consultations Vol. 5, No. 2 Treatment of a Never-Smoker With NSCLC 1 Nov 21, 2009
From Signal Transduction to Epigenetic Regulation of Gene Expression in Oncology: Challenging Clinical Cases Improving Outcomes for Patients With CML

Practical Issues in the Management of CLL

Targeting Epigenetics in Cancer

Emerging HDACI Combinations in Solid Tumors

Roundtable Discussion 		1 Nov 20, 2009
Case Studies in Oncology Vol. 9, No. 2 Treatment for Metastatic Pancreatic Cancer 1 Nov 18, 2009
Oncology Briefings Vol. 6, No. 7 Optimizing mTOR and VEGF Inhibitors in Advanced RCC 0.5 Nov 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 7 Bone Health in Hormone Receptor–Negative Early-Stage Breast Cancer 1 Nov 13, 2009
Case Studies in Breast Cancer Vol. 6, No. 6 Adjuvant Therapy for a Patient With HER2+ Breast Cancer and Borderline LVEF 1 Nov 12, 2009
Refining and Personalizing Treatment for Non–Small-Cell Lung Cancer Current Approaches With EGFR Inhibitors in NCSLC

Approaches to Inhibit Angiogenesis: Targeting the Ligand

Small-Molecule VEGFR TKIs

Class-Effect Toxicities With Antiangiogenic Agents



Moving Toward Individualized Cancer Therapy for NSCLC 		1 Nov 3, 2009
Case Studies in Oncology Vol. 9, No. 3 GBM: Advances and Challenges 1 Oct 31, 2009
Cancer Summaries & Commentaries Vol. 1, No. 4 Targeted Strategies for Metastatic and Locally Advanced NSCLC 1 Oct 31, 2009
Expanding Options for the Treatment of Metastatic Breast Cancer Novel Inhibitors of HER2

Combination Chemotherapy in MBC

First-line Therapy for Aggressive Metastatic Disease

Angiogenesis: VEGF- and VEGFR-Targeted Therapies 		1 Oct 29, 2009
Advances in Lung Cancer Vol. 8, No. 1 Targeted Agents in Early-Stage and Locally Advanced NSCLC

Safety of Antiangiogenic Agents in Advanced NSCLC

Optimizing Chemotherapy in Resectable NSCLC

 		1 Oct 27, 2009
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 2 2008 Oncology Conference Highlights

Genomic Profiling Identifies CLL Subtypes

MRD Negativity and Consolidation Therapy in CLL
 		1 Oct 17, 2009
New Therapeutic Options for Challenging Hematologic Diseases Clinical Value of IPSS Risk Assessment

Extending Outcomes in MDS

Patient With AML in First Complete Remission

Management of a 28-Year-Old Patient With PNH 		1 Oct 17, 2009
Case Studies in Breast Cancer Vol. 6, No. 5 HER2+ Breast Cancer Progressing After Adjuvant Therapy 1 Sep 29, 2009
Case Studies in Pain Management Vol. 2, No. 2 Nociceptive and Neuropathic Pain Management 1 Sep 29, 2009
In-Depth Tumor Board: Biologic Therapy for Breast Cancer Anti-HER2 Therapy for Node-Negative Breast Cancer

Cardiotoxicity and Anti-HER2 Therapy

Refractory HER2+ MBC

Antiangiogenic Therapy for MBC

Chemotherapy Options for MBC 		1 Sep 24, 2009
Case Studies in Oncology Vol. 9, No. 1 Gemcitabine-Refractory Pancreatic Cancer 1 Sep 24, 2009
Case Studies in Breast Cancer Vol. 6, No. 3 Neoadjuvant Treatment of HER2+ IBC 1 Sep 12, 2009
Biological Therapy of Breast Cancer Vol. 9, No. 1 Antiangiogenic Agents in Breast Cancer

Combining Targeted Agents in Breast Cancer

Molecular Aberrations in Breast Cancer and Future Therapy 		1 Sep 12, 2009
Case Studies in Breast Cancer Vol. 6, No. 4 Late-Extended Treatment of Breast Cancer With an AI 1 Sep 12, 2009
Oncology Briefings Vol. 6, No. 5 Optimizing the Chemotherapy Backbone in Metastatic NSCLC 0.5 Sep 2, 2009
Receptor-Based Therapeutics: An Interactive Exposé Personalized Cancer Therapy

Options for ErbB2-Positive MBC That Has Progressed on ErbB2-Targeted MoAb Therapy

Antiangiogenic Therapy in Newly Diagnosed MBC 		1 Aug 27, 2009
Cancer Summaries & Commentaries Vol. 1, No. 2
Broadening the Horizon of Targeted Agents in Advanced Non–Small-Cell Lung Cancer Safety of Bevacizumab in Advanced NSCLC With Treated or Untreated CNS Metastases

Pemetrexed/Carboplatin Plus Bevacizumab in Advanced Nonsquamous NSCLC

Paclitaxel/Carboplatin With or Without CP-751871 as First-line Therapy for Advanced NSCLC

rhApo2L/TRAIL Plus Paclitaxel/Cisplatin/Bevacizumab in Advanced Nonsquamous NSCLC

XL647 in Patients With NSCLC and Acquired Resistance to Gefitinib or Erlotinib

1 Aug 26, 2009
The Next Generation of Combinations for Breast Cancer: Building on Targeted Therapies
Online Only Cancer Summaries & Commentaries Dual HER1/HER2 Inhibition in Refractory MBC

Every-3-Week Trastuzumab-MCC-DM1 in HER2+ MBC

Everolimus/Paclitaxel/Trastuzumab in Trastuzumab-Resistant HER2+ MBC

Neoadjuvant Letrozole/Everolimus in ER+ Breast Cancer

Vorinostat/Tamoxifen in AI-Resistant ER+ MBC 		1 Aug 22, 2009
Cancer Summaries and Commentaries Vol. 1, No. 1

Bevacizumab/Docetaxel in Advanced Breast Cancer

Lapatinib With or Without Pazopanib in HER2-Positive MBC

Trastuzumab/Pertuzumab for MBC That Had Progressed on Prior Trastuzumab

Tanespimycin/Trastuzumab in HER2-Positive MBC That Had Progressed on Prior Trastuzumab

Anastrozole/Gefitinib in Postmenopausal Women With Hormone Receptor–Positive MBC

Cetuximab With or Without Carboplatin for Triple-Negative MBC

 		1 Aug 20, 2009
Case Studies in Breast Cancer Vol. 6, No. 2

First-line Treatment of HER2– MBC

 		1 Aug 20, 2009
Case Studies in Colorectal Cancer Vol. 4, No. 1 Extended Biologic Treatment of a Patient With Metastatic Colorectal Cancer 1 Jul 15, 2009
The Evolving Paradigm of Molecular-Based Diagnosis and Targeted Therapies in Breast Cancer How Do We Counsel Our Breast Cancer Patients?

Diagnostic Testing for Targeted Therapeutics: Lessons Learned From HER2

HER2-Targeted Therapy in the Adjuvant Treatment of Breast Cancer

Neoadjuvant Trastuzumab in HER2-Positive Breast Cancer 		1 Jun 30, 2009
Chronic Lymphocytic Leukemia: The Cutting Edge Vol. 13, No. 1 Chemoimmunotherapy Regimens in Chronic Lymphocytic Leukemia: Recent Updates

When and How to Treat Patients With Chronic Lymphocytic Leukemia

 		1 Jun 27, 2009
Case Studies in Pain Management Vol. 2, No. 1 Treatment of a Patient With Intractable Pain Due to Progressive Pancreatic Cancer 1 Jun 26, 2009
Case Studies in Ovarian Cancer Vol. 3, No. 1 Clinical Management of a Patient With Platinum-Resistant Ovarian Cancer 1 Jun 6, 2009
Oncology Consultations Vol. 5, No. 1 Therapeutic Options for ER+/HER2- Breast Cancer 1 Jun 6, 2009
Patient Communication: The Surgeon's Role Interpretation of Breast Cancer Biomarkers

Reviewing Individualized Benefits and Side Effects of Systemic Therapy: Decision Tools

Communicating the Promises and Limitations of Targeted Therapy

The Impact of Advocacy in Cancer Care and Research

Learning How to Counsel Our Patients

 		1 Jun 6, 2009
Molecular Profiling:Improving Precision in Adjuvant Therapy Decisions for Early-Stage Breast Cancer

Multigene Assays: A Window Into Breast Cancer Behavior

1 Jun 4, 2009
From Genome to Clinic: Translating Discoveries Into Practice

Targeting Growth Factor Receptors: Current Impact and Future Potential


Therapeutic Applications of Angiogenesis-Based Therapies

 		1 Jun 4, 2009
Rapid Reviews in Oncology: Update in Hematologic Malignancies Frontline Therapies for Multiple Myeloma: A New Landscape

Evolving Strategies in the Management of Patients With Chronic Lymphocytic Leukemia

Clinical Advances for Patients With Myelodysplastic Syndromes

 		1 Jun 3, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 3 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma 1.5 May 28, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 1 Novel Agents for Hematologic Malignancies: An Era of Riches 1.25 May 27, 2009
Clinical Lymphoma & Myeloma Vol. 8, Suppl. 2 Dose-Intense and Dose-Dense Regimens in Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma 1 May 27, 2009
Clinical Colorectal Cancer Vol. 7, Suppl. 1 New Developments in Targeted Treatment Strategies for Colorectal Cancer 1.25 May 27, 2009
Clinical Challenges in Non-Hodgkin Lymphoma: Biologic Strategies for 2008

Improving Outcomes in DLBCL by Altering Current Regimens


Biologic Therapy in CLL: Current Data and Ongoing Studies


Novel Anti-CD20 Antibodies in NHL


Current Trends in Antiangiogenic Therapy in NHL


Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma

 		1 May 15, 2009
Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer The Success of Targeting the Vascular Endothelial Growth Factor Receptor Axis in Renal Cell Carcinoma

Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent Renal Cell Carcinoma

Risk Prognostication and Tumorigenesis in Prostate Cancer

Current Approaches to Prevention and Early Intervention in Prostate Cancer

 		1 May 14, 2009
Breast Cancer Journal Club Vol. 5, No. 2 Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer

Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab

Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC

Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer 		1 May 5, 2009
Case Studies in Breast Cancer Vol. 6, No. 1 ErbB TKIs in ErbB2-Positive IBC 1 May 5, 2009
Case Studies in Lymphoma Vol. 6, No. 2 This activity is intended for medical oncologists and hematologists involved in the care of patients with peripheral T-cell lymphoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. 1 May 5, 2009
Controversies in Adjuvant Endocrine Therapy for Breast Cancer Adjuvant Endocrine Therapy in 2007: What Have We Accomplished and What Uncertainties Remain?

Optimizing Endocrine Therapy for Patients With Newly Diagnosed Early-Stage Breast Cancer

Controversies in Adjuvant Endocrine Therapy: Extending Therapy Beyond 5 Years

Should All Patients Receiving Adjuvant Aromatase Inhibitors for Breast Cancer Receive Bisphosphonate Support? 		1 Apr 25, 2009
Practical Updates in Breast Cancer Adjuvant Chemotherapy for Early-Stage Breast Cancer 2 Apr 15, 2009
Clinical Challenges With Hereditary and Transfusion-Dependent Iron Overload
  • Hereditary Hemochromatosis and Iron Overload Disorders

  • Mechanisms of Action of Iron Chelating Agents

  • Current Perspectives in Measuring LIC

  • Managing Iron Overload in Transfusion-Dependent Patients

1 Apr 4, 2009
Case Studies in Lymphoma Vol. 6, No. 1 Romidepsin in MF and Histologic Large-Cell Transformation 1 Mar 17, 2009
Contemporary Trends in Chemotherapy for Advanced/Metastatic Breast Cancer The Dilemma of Single Versus Combination Therapy: Which Agents and What Clinical Situation?

Combinations of Chemotherapy and Biologically Targeted Agents: The Nature of the Synergy and Side-Effect Profile

Locally Advanced Breast Cancer as a Model for the Study and Optimization of Chemotherapeutic Regimens

The Use of Protein and Genetic Markers in Determining Optimal Chemotherapy: Ready for Prime Time? A Case-Based Debate

1 Mar 10, 2009
Practical Updates in Renal Cell Carcinoma

Utilizing Prognosis Assessment for Treatment Strategy Development in Metastatic Renal Cell Carcinoma


Case 1: A 65-year-old male


Case 2: A 48-year-old female


Case 3: A 64-year-old female

 		1 Mar 3, 2009
Oncology Consultations Vol. 4, No. 12 Treatment of HER2-Positive/Hormone Receptor Positive Metastatic Breast Cancer With Endocrine Therapy Plus HER2-Targeted Therapy 1 Mar 3, 2009
Targeted Therapies in Oncology
  • The Extrinsic Pathway: Targeting Death Receptors in Cancer Therapy

  • Targeting the Cell Cycle and DNA Repair Machinery for Cancer Therapy

 		1 Mar 3, 2009
Oncology Briefings Vol. 6, No.1 Update on Histone Deacetylase Inhibitors in the Treatment of T-Cell Lymphoma and Multiple Myeloma 0.5 Mar 3, 2009
Clinical Advances in Breast Cancer Vol. 1, No. 1 HER2-Positive Early-Stage Breast Cancer: Decision-Making and Practical Management

Role of Genomics and Emerging Novel Molecular Diagnostic Tests in the Routine Management of Early-Stage Breast Cancer

 		1 Mar 3, 2009
Clinical Breast Cancer Vol. 8, Suppl. 1 Dose-Dense Therapy in the Treatment of Early-Stage Breast Cancer: An Overview of the Data

Management of Febrile Neutropenia and Cardiac Toxicity in the Adjuvant Treatment of Breast Cancer

Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors

New Strategies for the Treatment of Metastatic Bone Disease

 		1.5 Mar 3, 2009
Oncology Briefings Vol. 6, No. 2 The Bcr-Abl kinase inhibitor imatinib is the current standard of care for the first-line treatment of patients with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). However, although imatinib yields durable remissions, it is not curative, and some patients have short-lived responses followed by disease progression. 0.5 Mar 3, 2009
Oncology Briefings Vol. 5, No. 4 Current and Novel Treatment Strategies for Newly Diagnosed Multiple Myeloma 0.5 Feb 15, 2009
Clinical Colorectal Cancer Vol. 6, Suppl. 2

First-Line Use of Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer
James J. Lee, Edward Chu

The Role of Epidermal Growth Factor Receptor–Targeted Antibody Therapy in Previously Treated Colorectal Cancer
David Watkins, David Cunningham

Combining Targeted Therapies to Enhance the Effectiveness of Chemotherapy in Patients with Treatment-Refractory Colorectal Cancer
Cathy Eng

Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer
Eric Van Custem

 		1.5 Jan 31, 2009
Oncology Consultations Vol. 4, No. 13 Multidisciplinary Management in Patients Presenting With Resectable or Borderline-Resectable Stage IV Colorectal Cancer

 		1 Jan 17, 2009
Angiogenesis in Oncology Vol. 2, No. 6 Current Status of Antiangiogenesis Therapy of Colorectal Cancer: Timing and Duration of Therapy

Combined Modality Therapy in Early-Stage Non-Small-Cell Lung Cancer: The Potential and Future Role of Antiangiogenic Agents

Targeting the Tumor Microenvironment 		1 Jan 17, 2009
Advances in Lung Cancer Vol. 7, No. 4 Newly Diagnosed, Advanced-Stage Non–Small-Cell Lung Cancer: Considerations for First-line Treatment

Second- and Third-line Treatment Options for Advanced Non–Small-Cell Lung Cancer

Agents Targeting Mammalian Target of Rapamycin and Heat Shock Protein 90 in Non-Small-Cell Lung Cancer

 		1 Jan 17, 2009

Highlighted Publications


Practical Updates in Renal Cell Carcinoma

Expiration Date: Mar 3, 2009


Angiogenesis in Oncology Vol. 2, No. 6

Expiration Date: Jan 17, 2009